Claret Medical is a medical device company developing innovative solutions for cerebral protection during structural heart and vascular interventions. The company was acquired by Boston Scientific (NYSE: BSX) in 2018.
Location: United States, California, Santa Rosa
Total raised: $18M
Investors 1
| Date | Name | Website |
| - | Lightstone... | lightstone... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.08.2014 | Series B | $18M | - |
Mentions in press and media 5
| Date | Title | Description |
| 25.08.2014 | Claret Medical Raises $18M Series B Funding | Claret Medical, a Santa Rosa, CA-based developer of products for cerebral protection during structural heart, vascular and cardiac surgery procedures, raised $18m Series B funding. The round was led by Santé Ventures with participation from... |
| 21.08.2014 | Claret Medical Secures $18M | SANTA ROSA, CA, Claret Medical, Inc., announced today that it has entered into an agreement for up to $18 million in a Series B financing. >> Click here for more funding data on Claret Medical >> To export Claret Medical fun... |
| 21.08.2014 | Claret Medical chases FDA win with $18M Series B for cerebral protection device | Claret Medical said today that it secured up to $18 million in Series B financing it plans to use to make progress toward the U.S. market. Claret said the new cash will help complete a U.S. pivotal trial of the Sentinel cerebral protection ... |
| 01.07.2013 | Claret Medical raises $3.6M through private offering | Updated July 8, 2013, at 5:30 a.m. company updates. The funds were raised through a private offering of convertible promissory notes. California-based medical device maker Claret Medical has raised $3.6 million so far through a private offe... |
| 04.11.2011 | Claret Medical raises $3.4M, lands CE Mark | Funding Roundup | Recently formed medical device maker Claret Medical, Inc. raised $3.38 million in a Series A private equity offering. The Santa Rosa, Calif.-based company raised $3.38 million out of the $3.5 million sought, according to an SEC report. Clar... |